ImmunoGen, Inc.
DelistedCIK 855654fmd_0ZZ396ZFTQJYW5HB1W46J0B1DPManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jul 01, 2009 to Sep 30, 2023, 54 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 60 | 86 | – | 49 | 115 | 53 | 82 | 132 | 70 | 109 |
| Research and development | 107 | 112 | – | 141 | 140 | 174 | 115 | 115 | 151 | 213 |
| Selling, general and administrative | – | – | – | – | – | – | – | 39 | 44 | 116 |
| Total operating expenses | 131 | 140 | – | 184 | 174 | 215 | 174 | 155 | 195 | 330 |
| Operating income | (72) | (54) | – | (136) | (59) | (161) | (92) | (22) | (125) | (221) |
| Interest expense | – | – | – | 2 | 3 | 0 | 0 | 0 | 0 | – |
| Other non-operating income (expense) | 0 | (1) | – | (1) | 1 | (1) | 1 | 0 | (1) | (1) |
| Income before taxes | (71) | (61) | (145) | – | (96) | (169) | (104) | (44) | (139) | (222) |
| Income tax expense | – | – | – | – | 0 | 0 | 0 | 0 | 0 | 1 |
| Net income from continuing operations | – | – | – | – | (96) | (169) | (104) | (44) | (139) | (223) |
| Net income | – | – | – | (157) | (96) | (169) | (104) | (44) | (139) | (223) |
| Net income to common shareholders | (71) | (61) | (145) | – | – | – | – | – | – | – |